Daptomycin seems to be responsible for most of the heterogeneity as sed to CHD or stroke

diuretic was prescribed for of C hypokalemi 9 of Stigmasterol A hypokalemi and 3 of L hypokalemics. For hyperkalemi open-label angiotensin-converting enzyme in-hibitor was prescribed for of C, of A, and of L. Discussion ALLHAT data show th in conventional practice settin notice of incident hypokalemia was not associated with adverse cardiovascular ou a although associated with increased total mortali the observed increase showed that appearance of hypokalemia is not likely topromise the proven cardiovascular benefit of diuretic therapy. In additi ALLHAT data show that hyperkalem although relatively rare and mostmon in patients randomized to L, was associated with increased total CVD oues. Our analysis was limited to ALLHAT participan ran-domized to C, A, or L, who had normal baseline K concentrations and repeat measurements between 0 and 4 months later.
These participants did not markedly differ from the entire trial population in demo-Downloaded from hyper.ahajournals/ at New York University/ Medical Center New York on March 7, Hypertension May Table . Overall Cumulative No. of Events and -Y Kaplan-Meier Telaprevir clinical trial Event Rates per for the Hyperkalemic and Normal Y Potassium Subgroups No. of Events -Y Rate per Cox Proportional Hazard Models HypoK /Normal Drug Interaction Adjusted Non-CVD Also depicted are Cox proportional H corresponding 5 C and P values for the hyperkalemia/normalparisons and for the drug group by y serum potassium interaction tests: hyperkalemia/normal A/C and hyperkalemia/normal L/C. Participants with baseline potassium mmol/L or mmol/L were excluded.
A indicates amlodipine; C, chlorthalidone; CC bined cardiovascular disease; C coronary heart disease; C cardiovascular disease; heart failure; Cidofovir structure hazard ratio; L, lisinopril. nadjusted Cox model for each oue included only terms for the group and the K group relative to the normal potassium group; K The adjusted Cox model for each oue included main effects terms for hypokalemia/norm hyperkalemia/norm baseline characteristic: ag se rac type diabetes mellitu history CH history of other atherosclerotic CV cigarette smoke. baseline systolic blood pressure and serum potassi estimated glomerular filtration rate at y , drug treatment effect and interaction terms: the potassium main effects with each of the drug main effects . graphic and clinical characteristics.
As expect modest year hypokalemia was primarily an experience of participants randomized to C . Development of severe hypokalemia was less frequent . vascular o and they actually had lower rates of cardiovascular events than the hypokalem normokalem CCI-779 solubility or hyperkalemic subgroups of either L or A participants. For CVD ou HF seems to be responsible for most of the heterogeneity as sed to CHD or stroke. There was less By contra hyperkalemia occurred primarily in L HF in Cpared with A or L. Overall mortality among participants and was leastmon gold among C partici-pants . Potassium supplements were prescribed to 0 of participants. The availability and use of potassium supplements suggest that clinical ca in ALLH is likely to mirror conventional ca a th the CVD oues of interest in regard to incident hypokalemia are likely to be generally applicable in settings where clinicians are free to respond appropriately to this laboratory finding.